覆盖细胞淋巴瘤:用布鲁顿氨酸激酶向方法进行最佳治疗
Toby A Eyre1, Chan Y Cheah2, Clémentine Sarkozy3,4,5
1Oxford Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Churchill Drive, Oxford, United Kingdom.
概括
协同布鲁顿氨酸激酶 (cBTK) 抑制剂对复发的地幔细胞淋巴瘤 (MCL) 有效. 最近的数据表明cBTK抑制剂也可能受益于一线MCL治疗,建议使用治疗算法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 是一种罕见的淋巴瘤,存活率较低.
- 协同布鲁顿氨酸激酶 (cBTK) 抑制剂在复发性MCL中有效.
- 目前对复发性MCL的标准治疗包括cBTK抑制剂单疗法.
研究的目的:
- 审查最近关于将cBTK抑制剂整合到一线MCL治疗中的数据.
- 在初始治疗环境中评估cBTK抑制剂的证据.
- 建议一线MCL的治疗算法,包括cBTK抑制剂.
主要方法:
- 审查最近的II期和随机II/III期临床试验.
- 对支持在一线治疗中添加cBTK抑制剂的数据的分析.
- 讨论治疗策略和治疗算法开发.
主要成果:
- 多个临床试验表明,在一线治疗中添加cBTK抑制剂有好处.
- 强有力的证据支持将cBTK抑制剂纳入初始MCL治疗.
- 数据表明cBTK抑制剂是用于一线使用的高度活性小分子.
结论:
- 共价BTK抑制显示出对MCL的第一线治疗有前途.
- 将cBTK抑制剂整合到一线治疗中得到了最近的临床数据的支持.
- 治疗算法被提议用于cBTK抑制剂的未来第一线使用.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
